Why GLP-1s Need Behavioral Coaching to Work

Employer Coverage Is Expanding, but Cost Pressure Is Real

GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, have become the most disruptive force in employer-sponsored health benefits in a generation. Coverage for weight-loss indications jumped from 28% to 43% among firms with 5,000+ employees between 2024 and 2025, according to the Kaiser Family Foundation.

But the cost math is daunting. GLP-1 claims rose from 6.9% to 10.5% of total pharmacy spend in just two years, and some employers report 30% year-over-year cost increases. At $10,000+ per member annually before rebates, the financial trajectory is unsustainable without better utilization management.

According to Blue Cross Blue Shield and EBRI modeling, employer health premiums could increase by as much as 14% from GLP-1 coverage alone, even with access restricted to the highest-need patients. GLP-1s now account for more than 15% of annual claims for over a quarter of employers.

The recruitment angle complicates the picture further. Nearly one-third of employees say GLP-1 coverage could influence employment decisions, making it a talent retention lever employers cannot easily dismiss.

The Discontinuation Problem: Why Medication Alone Fails

GLP-1 medications are clinically effective. Patients lose an average of 14.9% of body weight over 68 weeks, with cardiovascular event risk dropping by 20%. The problem is what happens after patients stop taking them.

A 2025 meta-analysis published in eClinicalMedicine (The Lancet) found significant metabolic rebound after GLP-1 discontinuation. Patients regained an average of 5.63 kg overall, and semaglutide/tirzepatide users regained approximately 9.69 kg.

49%of patients who lost weight on GLP-1s exceeded their original weight within 12 months of stopping, according to a meta-analysis in Obesity Reviews.

Longer follow-up periods produced worse results. Patients tracked beyond 26 weeks regained 7.31 kg compared to 2.51 kg for shorter follow-ups. Medication adherence was equally concerning: the Journal of Managed Care & Specialty Pharmacy reported fewer than one-third of patients stayed on GLP-1s for a full year, and only 27% took medications as intended.

There is also a body composition concern. Up to 39% of weight lost on GLP-1s comes from lean muscle mass rather than fat, creating downstream risks for musculoskeletal pain, falls, and disability. This makes concurrent exercise and strength-training programs especially urgent, and it is one reason why health coaches supporting GLP-1 patients need specialized training.

Behavioral Coaching Dramatically Improves GLP-1 Outcomes

The evidence is converging from peer-reviewed journals, real-world clinical programs, and employer outcomes data. When structured behavioral coaching is paired with GLP-1 therapy, patients achieve better adherence, greater weight loss, and longer-lasting results.

Peer-Reviewed Evidence

Sforzo et al. (2024), published in the American Journal of Lifestyle Medicine, found that health and well-being coaching (HWC) improves medication adherence and promotes healthy behavior change when used as an adjuvant to GLP-1 therapy. The authors noted the combined approach shows strong theoretical and observational support, though prospective clinical trials are still needed.

Digital Engagement Data

A 2025 study in the Journal of Medical Internet Research found that engagement with a digital weight management platform significantly enhanced weight loss outcomes among GLP-1 users. The study described the combination of pharmacotherapy and digital behavioral support as “a promising strategy for obesity management.”

15.6%average weight loss at 12 months achieved by a Cleveland Clinic telehealth program combining GLP-1 therapy with intensive lifestyle coaching for 2,600+ participants. 73% of diabetic/prediabetic participants reached A1C < 5.7%.

PBM and Employer Partnerships

Most major PBMs have announced partnerships with wellness vendors, recognizing that medication-only approaches produce unsustainable cost trajectories. According to Mercer’s 2026 guidance, some programs pair short-term GLP-1 therapy with deprescribing pathways, while others offer wraparound coaching and nutrition support.

Members using comprehensive digital support alongside GLP-1s stick to weight-loss goals 32% longer, according to Digital Health Insights. This improved adherence directly translates to better outcomes and lower long-term costs for employers.

Employers Are Mandating Lifestyle Programs as a Coverage Condition

The employer response to GLP-1 cost and efficacy concerns is increasingly structural, not just financial. According to Mercer, 38% of employers now require participation in behavior-change programs as a condition of GLP-1 coverage. Another 28% are considering adding this requirement for 2026.

According to OneDigital’s strategic decision guide, 49% of employers require clinical criteria beyond FDA guidelines, including mandatory participation in lifestyle or weight management programs. 34% of employers covering GLP-1s require employees to meet with a dietitian, case manager, therapist, or participate in a structured lifestyle program.

Employer Approach	Prevalence (2025-2026)
Cover GLP-1s with mandatory lifestyle program	38% of employers
Require clinical criteria beyond FDA label	49% of employers
Require dietitian/therapist participation	34% of employers
Considering adding lifestyle requirement for 2026	28% of employers
Using prior authorization for access	Widespread, increasing

The Emotional Eating Gap Medication Cannot Close

Up to 60% of individuals seeking weight loss treatment report engaging in emotional eating behaviors, according to Digital Health Insights. GLP-1s reduce appetite through physiological mechanisms, but they do not address the psychological and behavioral patterns that drive overeating.

This is precisely where cognitive behavioral approaches, motivational coaching, and habit-formation programs deliver value that medication cannot replicate. Addressing the root causes of disordered eating, including stress, emotional triggers, and ingrained habits, is essential for sustaining weight loss after medication ends. As Avidon Health CEO Clark Lagemann has discussed, integrating behavioral science with GLP-1 therapy is what separates short-term weight loss from lasting health improvement.

“Health and well-being coaching is documented to improve medication adherence and promote healthy behavior change when used as an adjuvant to GLP-1 induced weight loss.”
— Sforzo et al., American Journal of Lifestyle Medicine, 2024

Regulatory Shifts Make Behavioral Support Even More Urgent

The compounded GLP-1 market is closing. As of early 2026, the FDA has moved to enforce against non-approved compounded semaglutide and tirzepatide now that shortages are resolved. This eliminates the lower-cost compounded alternative and may push more demand toward employer-sponsored plans for FDA-approved versions.

Meanwhile, oral semaglutide and next-generation GLP-1/GIP dual agonists are in the pipeline, likely expanding the eligible patient population further, according to PwC’s analysis. Employers who lack a structured behavioral support framework will face accelerating cost pressure as access widens.

There are also legal considerations. Whether mandatory wellness program participation as a condition of GLP-1 coverage complies with ADA, GINA, and HIPAA nondiscrimination rules is still being tested, as Morgan Lewis has analyzed.

What Employers Should Look for in a GLP-1 Behavioral Partner

The market dynamics create a clear set of requirements for any workplace wellness platform supporting GLP-1 programs. Employers and benefits consultants, especially Mercer, are looking for evidence-based programs that can demonstrate improved adherence, sustained weight loss, and total cost-of-care reductions.

When employers require lifestyle program participation as a condition of coverage, they need a vendor who can deliver, document, and report on that participation. Platforms with coaching infrastructure, progress tracking, and outcomes measurement are positioned to fill this role.

The “GLP-1 wraparound” is becoming a product category. PBMs, health plans, and employers are actively seeking partners who address nutrition coaching, exercise programming (especially strength training to preserve lean mass), emotional eating interventions, habit formation, and medication adherence monitoring.

Deprescribing support remains underserved. Most existing programs focus on the medication phase, but the greater unmet need is supporting patients who are stepping down or discontinuing GLP-1s, where the regain data is most alarming.

Frequently Asked Questions

Why do employers require behavioral coaching with GLP-1 coverage?

Fewer than one-third of patients stay on GLP-1s for a full year, and most regain significant weight after stopping. Behavioral coaching improves medication adherence, builds sustainable habits around nutrition and exercise, and helps patients maintain results long after they step down from medication.

How much weight do people regain after stopping GLP-1 medications?

According to a 2025 meta-analysis in eClinicalMedicine, patients regain an average of 5.63 kg after GLP-1 discontinuation. Semaglutide and tirzepatide users regain approximately 9.69 kg. Nearly half of patients who lost weight exceeded their original weight within 12 months of stopping.

What percentage of employers cover GLP-1s for weight loss?

According to the 2025 Kaiser Family Foundation survey, 43% of employers with 5,000 or more workers now cover GLP-1 receptor agonists for weight loss indications. This is up from 28% in 2024. Coverage is near-universal for diabetes indications at 55% of employers.

Does behavioral coaching improve GLP-1 weight loss outcomes?

Yes. Research in the Journal of Medical Internet Research found that digital behavioral support significantly enhances weight loss outcomes for GLP-1 users. A Cleveland Clinic program combining GLP-1 therapy with lifestyle coaching achieved 15.6% average weight loss at 12 months, with 73% of diabetic participants reaching A1C below 5.7%.

How much could GLP-1 coverage increase employer health premiums?

BCBS and EBRI modeling shows employer health premiums could increase by as much as 14% from GLP-1 coverage alone, even with access restricted to the highest-need patients. GLP-1 claims rose from 6.9% to 10.5% of total pharmacy spend in just two years.

What is a GLP-1 wraparound program?

A GLP-1 wraparound program pairs medication with structured behavioral support, including nutrition coaching, exercise programming, emotional eating interventions, habit formation, and medication adherence monitoring. These programs address the gaps that medication alone cannot fill and help sustain results after patients taper off GLP-1s.

Sources

Author

Avidon Health Team
Avidon Health is transforming how organizations promote healthier lifestyles through behavior change science and technology-driven coaching. Our mission is to empower individuals to achieve better health outcomes while driving measurable business success for our clients.
With over 20 years of expertise in health coaching and cognitive behavioral training, we’ve built a platform that delivers personalized, 1-to-1 well-being experiences at scale.
Today, organizations use Avidon to reimagine engagement, enhance health, and create lasting behavior change—making wellness more accessible, impactful, and results-driven.